|
業務類別
|
Biotechnology |
|
業務概覽
|
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants. |
| 公司地址
| 1800 Owens Street, Suite 900, San Francisco, CA, USA, 94158 |
| 電話號碼
| +1 415 906-4324 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.vir.bio |
| 員工數量
| 367 |
| Mr. Brent Sabatini |
Senior Vice President and Chief Accounting Officer |
-- |
23/02/2026 |
| Ms. Vanina de Verneuil |
Executive Vice President, General Counsel and Corporate Secretary |
美元 506.33K |
16/04/2026 |
| Dr. Marianne De Backer, M.B.A.,M.Sc.,PhD |
Director, President and Chief Executive Officer |
美元 950.00K |
04/03/2026 |
| Mr. Jason O'Byrne |
Executive Vice President and Chief Financial Officer |
美元 534.42K |
16/04/2026 |
|
|
| Dr. Elliott Sigal, M.D.,PhD |
Independent Director |
16/04/2026 |
| Mr. Robert J. More |
Independent Director |
16/04/2026 |
| Dr. Vicki L. Sato, PhD |
Chairman of the Board |
16/04/2026 |
| Dr. Ramy Farid, PhD |
Independent Director |
16/04/2026 |
| Ms. Sona Saira Ramasastry, M.Phil,M.S. |
Independent Director |
16/04/2026 |
| Mr. Jeffrey S. Hatfield |
Independent Director |
16/04/2026 |
| Professor Dr. Norbert W. Bischofberger, PhD |
Independent Director |
16/04/2026 |
| Dr. Marianne De Backer, M.B.A.,M.Sc.,PhD |
Director, President and Chief Executive Officer |
04/03/2026 |
| Ms. Janet Napolitano, J.D. |
Independent Director |
16/04/2026 |
|
|
|
|
